Skip to content
CNS Clinical Research

Washington D.C., District of Columbia

CNS clinical trials in Washington D.C., DC

33 CNS studies are recruiting participants at sites in Washington D.C. as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Washington D.C. at a glance

  • 33 studies are recruiting at a site in Washington D.C..
  • By phase: Phase 1 (4), Phase 2 (1), Phase 3 (15), No phase (8), Observational (5). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (18), university, hospital or other (14), government (1).
  • By research area: Depression (7), Multiple Sclerosis (7), Migraine (6), Parkinson's Disease (6), Epilepsy (3), ADHD (2), Schizophrenia (2).
  • Most recent update to one of these records: November 12, 2026.

Depression studies recruiting in Washington D.C.

Basic details from each study's public record (the 30 most recently updated of 33). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Kaiser Permanente-Capitol Hill Medical Center · MedStar Georgetown University Hospital · MedStar Washington Hospital Center
    Registry record
    NCT06748222 · updated
  2. A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Children's National Medical Center
    Registry record
    NCT07227454 · updated
  3. Mindful Self-Compassion for Anxiety Disorders and Depression

    • No phase
    • Ages 18 to 75
    • All sexes
    Sponsor
    Georgetown University
    Study site
    Georgetown University Medical Center
    Registry record
    NCT05671419 · updated
  4. Does Social Media Impact Adolescent Mental Health?

    • No phase
    • Ages 10 to 14
    • All sexes
    Sponsor
    Georgetown University
    Study site
    Georgetown University
    Registry record
    NCT06049888 · updated
  5. Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method

    • No phase
    • Ages 18 to 65
    • All sexes
    Sponsor
    Georgetown University
    Study site
    Georgetown University Medical Center
    Registry record
    NCT07028216 · updated
  6. The Exhale Study: Treating Maternal Depression in an Urban Pediatric Asthma Clinic

    • No phase
    • All ages
    • All sexes
    Sponsor
    Children's National Research Institute
    Study site
    Children's National Hospital
    Registry record
    NCT06623981 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Schizophrenia studies recruiting in Washington D.C.

  1. Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

    • Phase 3
    • Ages 10 to 17
    • All sexes
    Sponsor
    Alkermes, Inc.
    Study site
    Alkermes Investigator Site
    Registry record
    NCT05303064 · updated
  2. BRAVE Program to Improve Safety and Reduce Violence Risk in Early Psychosis

    • No phase
    • Ages 16 to 30
    • All sexes
    Sponsor
    Howard University
    Study site
    Howard University Hospital
    Registry record
    NCT07417904 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Washington D.C., DC on ClinicalTrials.gov.

ADHD studies recruiting in Washington D.C.

  1. The Myelin Disorders Biorepository Project

    • Observational
    • All ages
    • All sexes
    Sponsor
    Children's Hospital of Philadelphia
    Study site
    Children's National Medical Center
    Registry record
    NCT03047369 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Washington D.C.

  1. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Washington Hospital Center ( Site 0098)
    Registry record
    NCT06841354 · updated
  2. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    MedStar Washington Hospital Center ( Site 5005)
    Registry record
    NCT06952504 · updated
  3. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Georgetown University
    Registry record
    NCT07174310 · updated
  4. A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

    • Phase 3
    • Ages 45 to 75
    • All sexes
    Sponsor
    BlueRock Therapeutics
    Study site
    MedStar Georgetown University Hospital
    Registry record
    NCT06944522 · updated
  5. RESvEraTrol in Parkinson's Disease (RESET)

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Georgetown University
    Study site
    Georgetown University Hospital
    Registry record
    NCT07592767 · updated
  6. Social & QoL Behaviors in Parkinson's Disease

    • Observational
    • Ages 40 and older
    • All sexes
    Sponsor
    Gregory Wallace
    Study site
    The George Washington University
    Registry record
    NCT06385184 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Washington D.C.

  1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    MedStar Georgetown University Hospital
    Registry record
    NCT03816345 · updated
  2. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT06433752 · updated
  3. Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    • Phase 3
    • Ages 40 to 70
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Medstar Washington Hospital Center
    Registry record
    NCT06846281 · updated
  4. Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT05877963 · updated
  5. A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study sites
    Georgetown University Hospital · Medstar Washington Hosp Ctr
    Registry record
    NCT07225504 · updated
  6. An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

    • Phase 1
    • Ages 18 to 60
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07224373 · updated
  7. AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Amylyx Pharmaceuticals Inc.
    Study site
    Georgetown University Hospital Pasquerilla Healthcare Center
    Registry record
    NCT06665165 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Epilepsy studies recruiting in Washington D.C.

  1. Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Neurona Therapeutics
    Study site
    George Washington University
    Registry record
    NCT05135091 · updated
  2. Artificial Intelligence for Brain MRI Analysis in Epilepsy

    • Observational
    • All ages
    • All sexes
    Sponsor
    Istituto Giannina Gaslini
    Study site
    George Washington University
    Registry record
    NCT07881185 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Migraine studies recruiting in Washington D.C.

  1. Dietary Intervention for Migraine Relief

    • No phase
    • Ages 18 to 75
    • All sexes
    Sponsor
    American University
    Study site
    American University
    Registry record
    NCT07360405 · updated
  2. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Children's National Medical Center
    Registry record
    NCT04649242 · updated
  3. Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Children's National Medical Center
    Registry record
    NCT04743141 · updated
  4. Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Velocity Clinical Research, Washington DC
    Registry record
    NCT05156398 · updated
  5. A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

    • Phase 1
    • Ages 6 to 11
    • All sexes
    Sponsor
    Pfizer
    Study site
    Velocity Clinical Research, Washington DC
    Registry record
    NCT06995729 · updated
  6. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Emerson Clinical Research Institute - Connecticut Avenue - Washington /ID# 231693
    Registry record
    NCT05125302 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Ask about studies near Washington D.C.

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call